Stock Information

• MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy
  Mon, Sep 28, 2026 2:45 PM
• Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript
  Mon, Sep 28, 2026 2:43 PM
• Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment
  Mon, Sep 28, 2026 12:38 PM
• Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
  Mon, Sep 28, 2026 12:00 PM
• FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals
  Mon, Sep 28, 2026 10:44 AM
• Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta - Slideshow
  Mon, Sep 28, 2026 10:17 AM
• Mirum Pharma's Brelovitug Meets Phase 3 Primary Endpoint In AZURE-1 Study For Chronic Hepatitis Delta Virus
  Mon, Sep 28, 2026 8:08 AM
• Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
  Sun, Sep 27, 2026 9:00 PM
• Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
  Fri, Sep 25, 2026 11:00 PM
• INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill
  Fri, Sep 25, 2026 6:43 PM

Financial data not available